Alphatec Holdings (NASDAQ:ATEC) Azioni

ALPHATEC HOLDINGS INC

Alphatec Holdings

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

Lake Street analyst Ben Haynor assumes Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy rating and announces Price Target of $18.

News

Price Target

Initiation

Analyst Ratings

ATEC

Lake Street Assumes Alphatec Holdings at Buy, Announces Price Target of $18

WIIM

Alphatec Holdings shares are trading higher after Piper Sandler raised its price target on the stock from $13 to $15.

Piper Sandler analyst Matt O'Brien reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and raises the price target from $13 to $15.

Reiteration

Piper Sandler Reiterates Overweight on Alphatec Holdings, Raises Price Target to $15

Needham analyst David Saxon reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $16 price target.

Needham Reiterates Buy on Alphatec Holdings, Maintains $16 Price Target

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) raises FY2025 sales outlook from $732.00 million to $734.00 million vs $732.46 million estimate.

Guidance

Alphatec Holdings Raises FY2025 Sales Guidance from $732.00M to $734.00M vs $732.46M Est

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.21) by 66.67 percent. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $169.18 million which beat the analyst consensus estimate of $168.18 million by 0.60 percent. This is a 20.00 percent increase over sales of $140.98 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Alphatec Holdings Q1 EPS $(0.35) Misses $(0.21) Estimate, Sales $169.18M Beat $168.18M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

HC Wainwright &amp; Co. analyst Sean Lee reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $20 price target.

HC Wainwright & Co. Reiterates Buy on Alphatec Holdings, Maintains $20 Price Target

Offerings

Reported Earlier, Alphatec Holdings Announced The Pricing Of Its Offering Of $350M Aggregate Principal Amount Of 0.75% Convertible Senior Notes Due 2030 In A Private Offering

Alphatec shares are trading lower after the company announced a proposed $300 million convertible senior note offering.

Alphatec Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced its intention to offer, subject to market and other conditions, $300,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). ATEC also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50,000,000 principal amount of notes.

ATEC Announces Proposed $300M Convertible Senior Notes Offering Due 2030

Alphatec shares are trading higher after Piper Sandler raised its price target on the stock from $12 to $13.

Piper Sandler analyst Matt O'Brien maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and raises the price target from $12 to $13.

Piper Sandler Maintains Overweight on Alphatec Holdings, Raises Price Target to $13

Alphatec Holdings shares are trading lower following a Q4 EPS miss.

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) affirms FY2025 sales outlook from $732.00 million to $732.00 million vs $731.39 million estimate.

Alphatec Holdings Affirms FY2025 Sales Guidance of $732.00M vs $731.39M Est

Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 37.84 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $176.79 million which beat the analyst consensus estimate of $172.49 million by 2.50 percent. This is a 28.14 percent increase over sales of $137.97 million the same period last year.

Alphatec Holdings Q4 EPS $(0.23) Misses $(0.19) Estimate, Sales $176.79M Beat $172.49M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Barclays analyst Matt Miksic maintains Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Overweight and raises the price target from $20 to $21.

Barclays Maintains Overweight on Alphatec Holdings, Raises Price Target to $21

Press Releases

ATEC to Present at the 2025 J.P. Morgan Healthcare Conference

Paragon 28 Appoints Dave Demski to Board of Directors

ATEC Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook

ATEC to Participate in Upcoming Conferences

ATEC Reports Fourth Quarter and Full Year 2024 Financial Results

ATEC Announces Proposed Convertible Senior Notes Offering

ATEC Prices Upsized $350.0 Million Convertible Senior Notes Offering

ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery

ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance

Lake Street

Piper Sandler

Needham

HC Wainwright & Co.

Barclays

Comments

Alphatec Holdings

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO